Lower Doses of CPX-351 as a Novel Approach for the Treatment of Older Patients With Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cytarabine/daunorubicin (Primary)
Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

03 Jan 2025 Planned End Date changed from 1 Dec 2026 to 1 Jun 2027.
03 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
10 Jul 2024 Planned End Date changed from 1 Jun 2026 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com